Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company, today announces the publication by expert clinicians of new consensus-based guidance - developed by them for the use of single-use negative pressure wound therapy (sNPWT) in closed surgical incisions. The guidance is supported by practical clinical practice recommendations for Germany and has been published in the internationally recognised journal of surgery Die Chirurgie. The new German consensus was supported by Smith+Nephew, a pioneer in sNPWT and manufacturer of the PICO™7 sNPWT system.
New guidelines link prevention strategies to improved health economics
A recently published interdisciplinary expert consensus suggests that prophylactic negative pressure wound therapy may not only improve clinical outcomes, but also positively influence key economic and operational indicators.¹ Postoperative wound healing complications and surgical site infections (SSIs) prolong treatment pathways and consume valuable healthcare resources.¹ The new German consensus is the first to translate clinical evidence into practical real-world guidance by recommending the targeted use of single-use negative pressure wound therapy (sNPWT) in high-risk patients, based on a risk score that supports transparent and reproducible clinical decision-making.¹
Complications linked to rising costs
Data also identifies the scale of economic challenge that is highly apparent within the healthcare system, where postoperative wound complications represent a significant and systematic cost driver that is not consistently reimbursed within the DRG system. The impact on key performance indicators in wound healing highlights the importance of standardised and economically sound treatment guidance4, for example:
- Length of stay: up to twice as long in patients with wound healing complications (18 vs. 9 days)⁴
- Staff workload: substantially increased (687.5 vs. 376 minutes)⁴
- Material costs: more than five times higher (€228 vs. €42)⁴
- Additional costs per case: approximately €2,850⁴
PICO 7 features support efficient use of hospital resources
Prophylactic use of NPWT has been proven to help prevent surgical site complications, significantly reducing the length of hospital stay.*3 Whilst a relevant consideration from both a clinical and economic perspective, for prevention strategies to succeed in routine practice they must integrate seamlessly into existing care pathways. PICO 7 device is a canister-free, portable, single-use negative pressure wound therapy system designed to deliver a negative pressure of –80 mmHg for up to 7 days. Importantly, it can be used in both inpatient and outpatient settings. The practical dressing change indicator, visual indicators for leak detection and battery status, and the availability of dressing sizes and configurations to accommodate different anatomical situations all combine to facilitate integration into established care pathways, and support continuity of therapy across all healthcare settings.
Enquiries
Frida Wilhelmsson +46 (738) 499-429
Smith+Nephew [email protected]
References
*Compared to care with standard dressings; p=0.0002; meta-analysis of 10 studies
[1] Karl T, Çetin SM, Mett TR, Bohlen KE, Wohlrab D. Die Einweg-Vakuumversiegelungstherapie zur Prävention von Wundheilungsstörungen bei primär verschlossenen Inzisionen: Internationaler Konsens und praxisnahe Empfehlungen für Deutschland. Die Chirurgie 07/2026.
2 Groenen H, Jalalzadeh H, Buis DR, et al. Incisional negative pressure wound therapy for the prevention of surgical site infection: an up-to-date meta-analysis and trial sequential analysis. EClinicalMedicine. 2023;62:102105. doi:10.1016/j.eclinm.2023.102105.
3 Saunders C, Nherera LM, Horner A, Trueman P. Single-use negative-pressure wound therapy versus conventional dressings for closed surgical incisions:systematic literature review and meta-analysis. BJS Open. 2021;5(1):1–8
4 Schubert T, Czenna V, Bauermeister R, Cramer J. Economic impact of wound healing disorders from a hospital perspective. Gesundheitsökonomie und Qualitätsmanagement. 2025. doi:10.1055/a-2458-0017.
About Smith+Nephew
Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 17,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.
Founded in Hull, UK, in 1856, we now operate in around 100 countries, and generated annual sales of $6.2 billion in 2025. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.
For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on X, LinkedIn, Instagram or Facebook.
Forward-looking Statements
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, which is available on the SEC’s website at www. sec.gov, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.
◊ Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office.
